drug biopharma dive - Robuta Search

https://www.biopharmadive.com/news/merck-cidara-acquire-flu-antiviral-drug/805513/ Merck stakes $9.2B on Cidara and its long-acting flu drug | BioPharma Dive The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative to vaccines for flu prevention. long acting merck stakes https://www.biopharmadive.com/news/FDA-approve-velsipity-etrasimod-ulcerative-colitis-pfizer/696551/ Pfizer wins FDA approval for its $7B colitis drug | BioPharma Dive Acquired with the buyout of Arena Pharmaceuticals, Velsipity enters a competitive market for ulcerative colitis pills. wins fda approval pfizer drug https://www.biopharmadive.com/news/eli-lilly-nexus-manufacturing-factory-acquire/713897/ Lilly to buy injectable drug plant in manufacturing ramp-up | BioPharma Dive The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes... injectable drug lilly buy plant Sponsored https://www.vixen.com/ VIXEN: Exclusive 4K Videos with the World’s Most Beautiful Women Watch the most beautiful women in the world brought to life through cinematic visuals, passionate storytelling, and premium-quality scenes... https://www.biopharmadive.com/news/viking-obesity-drug-phase-1-data-ozempic/646162/ Viking joins obesity drug development race with early study data | BioPharma Dive The biotech is working on a dual-acting weight loss treatment that could compete with medicines from Novo Nordisk, Eli Lilly and others. obesity drug early study viking https://www.biopharmadive.com/news/roches-oral-sma-drug-scores-in-older-patients/567047/ Roche's oral SMA drug scores in older patients | BioPharma Dive older patients roche oral sma https://www.biopharmadive.com/news/fda-rejects-akebia-anemia-drug-vadadustat/621304/ FDA rejects Akebia drug, dealing another blow to anemia pills | BioPharma Dive fda rejects drug dealing akebia Sponsored https://cams.com/ Cams.com - Free Sex Cams, Live Sex Chat 24/7 Live sex cams, watch and go one on one with your favorite model at Cams.com 🔥 Join free. https://www.biopharmadive.com/news/ptc-therapeutics-layoffs-jobs-translarna-ema/695154/ PTC to lay off more staff following drug setback in Europe | BioPharma Dive The biotech is expanding cuts it announced a few months ago after the EMA decided against renewing a conditional clearance for its drug Translarna. staff following ptc lay drug https://www.biopharmadive.com/news/roche-abbvie-venclexta-acute-myeloid-leukemia/574680/ Leukemia drug from Roche, AbbVie extends survival, study finds | BioPharma Dive Paired with chemotherapy, Venclexta succeeded in a Phase 3 acute myeloid leukemia trial just weeks after falling short in another combination study. leukemia drug extends survival https://www.biopharmadive.com/news/novartis-lutathera-first-line-cancer-study-success/694606/ Novartis radiopharmaceutical drug succeeds in first-line gut cancer study | BioPharma Dive Novartis has made a large investment in targeted radiotherapies, sparking competition from fellow pharma companies and young biotechs. drug succeeds first line gut https://www.biopharmadive.com/news/parp-inhibitor-esmo-astrazeneca-gsk-abbvie/563803/ AstraZeneca, Merck strengthen lead in PARP drug class | BioPharma Dive drug class biopharma dive merck https://www.biopharmadive.com/news/eli-lilly-tirzepatide-diabetes-novo-nordisk/596155/ Lilly says diabetes shot outperformed rival Novo drug in study | BioPharma Dive lilly says novo drug diabetes https://www.biopharmadive.com/news/fda-fibrogen-advisers-vote-roxadustat-anemia/603458/ FDA advisers push back on FibroGen anemia drug | BioPharma Dive Safety worries led to a near-unanimous vote against roxadustat in kidney disease patients, dimming the approval chances of what would be the first pill to... drug biopharma dive push back https://www.biopharmadive.com/news/lilly-terminate-obesity-trial-bimagrumab-muscle-diabetes/761105/ Lilly stops trial of muscle-sparing obesity drug | BioPharma Dive Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in people taking weight loss... drug biopharma dive lilly stops https://www.biopharmadive.com/news/merck-blackstone-adc-royalty-deal-sac-tmt/804597/ Blackstone pays Merck $700M to buy into ADC drug royalties | BioPharma Dive The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and... blackstone pays merck buy adc https://www.biopharmadive.com/news/cbo-estimate-pelosi-drug-plan-369b-savings-reduce-research/564962/ Pelosi drug plan would save $370B, but could reduce R&D, forecasters say | BioPharma Dive plan would could reduce pelosi https://www.biopharmadive.com/news/cytokinetics-fda-advisory-committee-vote-heart-failure/638762/ Cytokinetics heart drug voted down by FDA panel | BioPharma Dive Following years of development, the biotech’s heart failure drug now faces another hurdle in its regulatory path forward, after a group of FDA advisers took... cytokinetics heart drug voted https://www.biopharmadive.com/news/sanofi-ms-drug-tolebrutinib-FDA-clinical-hold-liver/626380/ FDA halts tests of Sanofi drug, acquired in $3.7B buyout, due to side effects | BioPharma Dive Liver problems in trial volunteers led the agency to curtail studies of the drug, marking the second major setback related to Sanofi’s acquisition of... fda halts tests sanofi drug https://www.biopharmadive.com/news/abbvie-landos-acquire-deal-immune-crohns-colitis/711225/ AbbVie to buy immune drug developer Landos | BioPharma Dive Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s. drug developer biopharma dive https://www.biopharmadive.com/news/gilead-hiv-lenacapavir-sunlenca-european-approval/630170/ Gilead breaks through with first approval for new HIV drug | BioPharma Dive European authorities cleared Gilead’s long-acting shot for patients whose HIV infection is resistant to other drugs. An FDA decision is expected by December. hiv drug gilead breaks first new https://www.biopharmadive.com/news/aimmune-fda-approval-palforzia-peanut-allergy/571524/ FDA approves Aimmune drug as first treatment for peanut allergy | BioPharma Dive fda approves peanut allergy https://www.biopharmadive.com/news/novo-nordisk-wegovy-obesity-heart-cardiovascular-select-protect/690195/ Novo obesity drug protects heart health in large trial | BioPharma Dive 2023 was a breakout year for GLP-1 drugs, which have shown dramatic weight loss benefits. Study results in August proved Novo’s Wegovy could protect the... obesity drug heart health novo https://www.biopharmadive.com/news/sanofi-amlitelimab-eczema-atopic-dermatitis-drug-results/810353/ Sanofi to seek approval of touted eczema drug despite mixed results | BioPharma Dive Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U.S. but has murky sales prospects. seek approval eczema drug mixed https://www.biopharmadive.com/news/merck-enflonsia-rsv-antibody-fda-approval-clesrovimab/750123/ Merck antibody drug for RSV approved by FDA | BioPharma Dive Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly became a blockbuster medicine... antibody drug biopharma dive https://www.biopharmadive.com/news/sarepta-duchenne-muscular-dystrophy-ppmo-results/599447/ Sarepta's second-gen Duchenne drug shows signs of topping its first | BioPharma Dive second gen duchenne drug shows